Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening.

Orazio Fortunato Veronica Huber Miriam Segale Agata Cova Viviana Vallacchi Paola Squarcina Licia Rivoltini Paola Suatoni Gabriella Sozzi Ugo Pastorino Mattia Boeri

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2022)

Implementing LDCT screening trials with minimally invasive blood tests could help reduce unnecessary procedures and optimize cost-effectiveness.

Keyphrases

minimally invasive